APO Research
Talk to an analyst

APO RESEARCH · REPORT

Kidney (Renal) Fibrosis

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Kidney (Renal) Fibrosis Market Analysis and Forecast 2026-2032

22 December 2025195 pages

Choose your research edition.

Industry ResearchKidney (Renal) Fibrosis Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Kidney (Renal) Fibrosis Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Kidney (Renal) Fibrosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Kidney (Renal) Fibrosis Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Kidney (Renal) Fibrosis Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Kidney (Renal) Fibrosis market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Kidney (Renal) Fibrosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Kidney (Renal) Fibrosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Kidney (Renal) Fibrosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Kidney (Renal) Fibrosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Kidney (Renal) Fibrosis include Merck, Roche, Pfizer, ProMetic Life-Sciences Inc., La Jolla Pharmaceutical Company, InterMune, Genzyme Corporation, Galectin Therapeutics and BioLine Rx Ltd, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Kidney (Renal) Fibrosis, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Kidney (Renal) Fibrosis, also provides the revenue of main regions and countries. Of the upcoming market potential for Kidney (Renal) Fibrosis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Kidney (Renal) Fibrosis revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Kidney (Renal) Fibrosis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Kidney (Renal) Fibrosis revenue, projected growth trends, production technology, application and end-user industry.

Kidney (Renal) Fibrosis Segment by Company

Merck

Roche

Pfizer

ProMetic Life-Sciences Inc.

La Jolla Pharmaceutical Company

InterMune

Genzyme Corporation

Galectin Therapeutics

BioLine Rx Ltd

Kidney (Renal) Fibrosis Segment by Type

Vasopeptidase Inhibitors

Angiotensin Converting enzyme (ACE) Inhibitors

Angiotensin II Receptor Blockers (ARBs)

Renin Inhibitors

Pirfenidone

Kidney (Renal) Fibrosis Segment by Application

Clinic

Hospital

Research Center

Kidney (Renal) Fibrosis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney (Renal) Fibrosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Kidney (Renal) Fibrosis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney (Renal) Fibrosis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Kidney (Renal) Fibrosis in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Kidney (Renal) Fibrosis company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Kidney (Renal) Fibrosis revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Kidney (Renal) Fibrosis Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Vasopeptidase Inhibitors Major Player Table 3. Angiotensin Converting enzyme (ACE) Inhibitors Major Player Table 4. Angiotensin II Receptor Blockers (ARBs) Major Player Table 5. Renin Inhibitors Major Player Table 6. Pirfenidone Major Player Table 7. Global Kidney (Renal) Fibrosis Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Clinic Major Player Table 9. Hospital Major Player Table 10. Research Center Major Player Table 11. Kidney (Renal) Fibrosis Industry Trends Table 12. Kidney (Renal) Fibrosis Industry Drivers Table 13. Kidney (Renal) Fibrosis Industry Opportunities and Challenges Table 14. Kidney (Renal) Fibrosis Industry Restraints Table 15. Global Kidney (Renal) Fibrosis Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Kidney (Renal) Fibrosis Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Kidney (Renal) Fibrosis Market Share by Region (2021-2026) Table 18. Global Kidney (Renal) Fibrosis Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Kidney (Renal) Fibrosis Market Share by Region (2027-2032) Table 20. Global Kidney (Renal) Fibrosis Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Kidney (Renal) Fibrosis Revenue Market Share by Players (2021-2026) Table 22. Global Kidney (Renal) Fibrosis Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Kidney (Renal) Fibrosis Key Players Headquarters & Area Served Table 24. Global Kidney (Renal) Fibrosis Players, Product Type & Application Table 25. Global Kidney (Renal) Fibrosis Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Kidney (Renal) Fibrosis by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Kidney (Renal) Fibrosis Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Kidney (Renal) Fibrosis Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Kidney (Renal) Fibrosis Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Kidney (Renal) Fibrosis Revenue Market Share by Type (2021-2026) Table 32. Global Kidney (Renal) Fibrosis Revenue Market Share by Type (2027-2032) Table 33. Global Kidney (Renal) Fibrosis Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Kidney (Renal) Fibrosis Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Kidney (Renal) Fibrosis Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Kidney (Renal) Fibrosis Revenue Market Share by Application (2021-2026) Table 37. Global Kidney (Renal) Fibrosis Revenue Market Share by Application (2027-2032) Table 38. Merck Company Information Table 39. Merck Business Overview Table 40. Merck Kidney (Renal) Fibrosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Merck Kidney (Renal) Fibrosis Product Portfolio Table 42. Merck Recent Development Table 43. Roche Company Information Table 44. Roche Business Overview Table 45. Roche Kidney (Renal) Fibrosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Roche Kidney (Renal) Fibrosis Product Portfolio Table 47. Roche Recent Development Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Kidney (Renal) Fibrosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Pfizer Kidney (Renal) Fibrosis Product Portfolio Table 52. Pfizer Recent Development Table 53. ProMetic Life-Sciences Inc. Company Information Table 54. ProMetic Life-Sciences Inc. Business Overview Table 55. ProMetic Life-Sciences Inc. Kidney (Renal) Fibrosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. ProMetic Life-Sciences Inc. Kidney (Renal) Fibrosis Product Portfolio Table 57. ProMetic Life-Sciences Inc. Recent Development Table 58. La Jolla Pharmaceutical Company Company Information Table 59. La Jolla Pharmaceutical Company Business Overview Table 60. La Jolla Pharmaceutical Company Kidney (Renal) Fibrosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. La Jolla Pharmaceutical Company Kidney (Renal) Fibrosis Product Portfolio Table 62. La Jolla Pharmaceutical Company Recent Development Table 63. InterMune Company Information Table 64. InterMune Business Overview Table 65. InterMune Kidney (Renal) Fibrosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. InterMune Kidney (Renal) Fibrosis Product Portfolio Table 67. InterMune Recent Development Table 68. Genzyme Corporation Company Information Table 69. Genzyme Corporation Business Overview Table 70. Genzyme Corporation Kidney (Renal) Fibrosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Genzyme Corporation Kidney (Renal) Fibrosis Product Portfolio Table 72. Genzyme Corporation Recent Development Table 73. Galectin Therapeutics Company Information Table 74. Galectin Therapeutics Business Overview Table 75. Galectin Therapeutics Kidney (Renal) Fibrosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Galectin Therapeutics Kidney (Renal) Fibrosis Product Portfolio Table 77. Galectin Therapeutics Recent Development Table 78. BioLine Rx Ltd Company Information Table 79. BioLine Rx Ltd Business Overview Table 80. BioLine Rx Ltd Kidney (Renal) Fibrosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. BioLine Rx Ltd Kidney (Renal) Fibrosis Product Portfolio Table 82. BioLine Rx Ltd Recent Development Table 83. North America Kidney (Renal) Fibrosis Revenue by Type (2021-2026) & (US$ Million) Table 84. North America Kidney (Renal) Fibrosis Revenue by Type (2027-2032) & (US$ Million) Table 85. North America Kidney (Renal) Fibrosis Revenue by Application (2021-2026) & (US$ Million) Table 86. North America Kidney (Renal) Fibrosis Revenue by Application (2027-2032) & (US$ Million) Table 87. North America Kidney (Renal) Fibrosis Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. North America Kidney (Renal) Fibrosis Revenue by Country (2021-2026) & (US$ Million) Table 89. North America Kidney (Renal) Fibrosis Revenue by Country (US$ Million) & (2027-2032) Table 90. Europe Kidney (Renal) Fibrosis Revenue by Type (2021-2026) & (US$ Million) Table 91. Europe Kidney (Renal) Fibrosis Revenue by Type (2027-2032) & (US$ Million) Table 92. Europe Kidney (Renal) Fibrosis Revenue by Application (2021-2026) & (US$ Million) Table 93. Europe Kidney (Renal) Fibrosis Revenue by Application (2027-2032) & (US$ Million) Table 94. Europe Kidney (Renal) Fibrosis Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. Europe Kidney (Renal) Fibrosis Revenue by Country (2021-2026) & (US$ Million) Table 96. Europe Kidney (Renal) Fibrosis Revenue by Country (US$ Million) & (2027-2032) Table 97. China Kidney (Renal) Fibrosis Revenue by Type (2021-2026) & (US$ Million) Table 98. China Kidney (Renal) Fibrosis Revenue by Type (2027-2032) & (US$ Million) Table 99. China Kidney (Renal) Fibrosis Revenue by Application (2021-2026) & (US$ Million) Table 100. China Kidney (Renal) Fibrosis Revenue by Application (2027-2032) & (US$ Million) Table 101. Asia Kidney (Renal) Fibrosis Revenue by Type (2021-2026) & (US$ Million) Table 102. Asia Kidney (Renal) Fibrosis Revenue by Type (2027-2032) & (US$ Million) Table 103. Asia Kidney (Renal) Fibrosis Revenue by Application (2021-2026) & (US$ Million) Table 104. Asia Kidney (Renal) Fibrosis Revenue by Application (2027-2032) & (US$ Million) Table 105. Asia Kidney (Renal) Fibrosis Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 106. Asia Kidney (Renal) Fibrosis Revenue by Region (US$ Million) & (2021-2026) Table 107. Asia Kidney (Renal) Fibrosis Revenue by Region (US$ Million) & (2027-2032) Table 108. SAMEA Kidney (Renal) Fibrosis Revenue by Type (2021-2026) & (US$ Million) Table 109. SAMEA Kidney (Renal) Fibrosis Revenue by Type (2027-2032) & (US$ Million) Table 110. SAMEA Kidney (Renal) Fibrosis Revenue by Application (2021-2026) & (US$ Million) Table 111. SAMEA Kidney (Renal) Fibrosis Revenue by Application (2027-2032) & (US$ Million) Table 112. SAMEA Kidney (Renal) Fibrosis Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. SAMEA Kidney (Renal) Fibrosis Revenue by Country (2021-2026) & (US$ Million) Table 114. SAMEA Kidney (Renal) Fibrosis Revenue by Country (US$ Million) & (2027-2032) Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Kidney (Renal) Fibrosis Image Figure 2. Global Kidney (Renal) Fibrosis Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Kidney (Renal) Fibrosis Market Size Share 2021 VS 2025 VS 2032 Figure 4. Vasopeptidase Inhibitors Image Figure 5. Angiotensin Converting enzyme (ACE) Inhibitors Image Figure 6. Angiotensin II Receptor Blockers (ARBs) Image Figure 7. Renin Inhibitors Image Figure 8. Pirfenidone Image Figure 9. Global Kidney (Renal) Fibrosis Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Kidney (Renal) Fibrosis Market Size Share 2021 VS 2025 VS 2032 Figure 11. Clinic Image Figure 12. Hospital Image Figure 13. Research Center Image Figure 14. Global Kidney (Renal) Fibrosis Market Size (US$ Million) & (2021-2032) Figure 15. Global Kidney (Renal) Fibrosis Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Kidney (Renal) Fibrosis Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Kidney (Renal) Fibrosis Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Kidney (Renal) Fibrosis Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Kidney (Renal) Fibrosis Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Kidney (Renal) Fibrosis Revenue Market Share by Type (2021-2032) Figure 22. Global Kidney (Renal) Fibrosis Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Kidney (Renal) Fibrosis Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Kidney (Renal) Fibrosis Revenue Market Share by Application (2021-2032) Figure 25. North America Kidney (Renal) Fibrosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Kidney (Renal) Fibrosis Revenue Share by Type (2021-2032) Figure 27. North America Kidney (Renal) Fibrosis Revenue Share by Application (2021-2032) Figure 28. North America Kidney (Renal) Fibrosis Revenue Share by Country (2021-2032) Figure 29. United States Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Kidney (Renal) Fibrosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Kidney (Renal) Fibrosis Revenue Share by Type (2021-2032) Figure 34. Europe Kidney (Renal) Fibrosis Revenue Share by Application (2021-2032) Figure 35. Europe Kidney (Renal) Fibrosis Revenue Share by Country (2021-2032) Figure 36. Germany Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Kidney (Renal) Fibrosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Kidney (Renal) Fibrosis Revenue Share by Type (2021-2032) Figure 46. China Kidney (Renal) Fibrosis Revenue Share by Application (2021-2032) Figure 47. Asia Kidney (Renal) Fibrosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Kidney (Renal) Fibrosis Revenue Share by Type (2021-2032) Figure 49. Asia Kidney (Renal) Fibrosis Revenue Share by Application (2021-2032) Figure 50. Asia Kidney (Renal) Fibrosis Revenue Share by Region (2021-2032) Figure 51. Japan Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Kidney (Renal) Fibrosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Kidney (Renal) Fibrosis Revenue Share by Type (2021-2032) Figure 59. SAMEA Kidney (Renal) Fibrosis Revenue Share by Application (2021-2032) Figure 60. SAMEA Kidney (Renal) Fibrosis Revenue Share by Country (2021-2032) Figure 61. Brazil Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Kidney (Renal) Fibrosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Vasopeptidase Inhibitors
  • Angiotensin Converting enzyme (ACE) Inhibitors
  • Angiotensin II Receptor Blockers (ARBs)
  • Renin Inhibitors
  • Pirfenidone
Applications
  • Clinic
  • Hospital
  • Research Center
Companies covered
  • Merck
  • Roche
  • Pfizer
  • ProMetic Life-Sciences Inc.
  • La Jolla Pharmaceutical Company
  • InterMune
  • Genzyme Corporation
  • Galectin Therapeutics
  • BioLine Rx Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Kidney (Renal) Fibrosis Market by Type
  3. 1.2.1 Global Kidney (Renal) Fibrosis Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Vasopeptidase Inhibitors
  5. 1.2.3 Angiotensin Converting enzyme (ACE) Inhibitors
  6. 1.2.4 Angiotensin II Receptor Blockers (ARBs)
  7. 1.2.5 Renin Inhibitors
  8. 1.2.6 Pirfenidone
  9. 1.3 Kidney (Renal) Fibrosis Market by Application
  10. 1.3.1 Global Kidney (Renal) Fibrosis Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Clinic
  12. 1.3.3 Hospital
  13. 1.3.4 Research Center
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Kidney (Renal) Fibrosis Market Dynamics
  1. 2.1 Kidney (Renal) Fibrosis Industry Trends
  2. 2.2 Kidney (Renal) Fibrosis Industry Drivers
  3. 2.3 Kidney (Renal) Fibrosis Industry Opportunities and Challenges
  4. 2.4 Kidney (Renal) Fibrosis Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Kidney (Renal) Fibrosis Market Perspective (2021-2032)
  2. 3.2 Global Kidney (Renal) Fibrosis Growth Trends by Region
  3. 3.2.1 Global Kidney (Renal) Fibrosis Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Kidney (Renal) Fibrosis Market Size by Region (2021-2026)
  5. 3.2.3 Global Kidney (Renal) Fibrosis Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Kidney (Renal) Fibrosis Revenue by Players
  2. 4.1.1 Global Kidney (Renal) Fibrosis Revenue by Players (2021-2026)
  3. 4.1.2 Global Kidney (Renal) Fibrosis Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Kidney (Renal) Fibrosis Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Kidney (Renal) Fibrosis Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Kidney (Renal) Fibrosis Key Players Headquarters & Area Served
  7. 4.4 Global Kidney (Renal) Fibrosis Players, Product Type & Application
  8. 4.5 Global Kidney (Renal) Fibrosis Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Kidney (Renal) Fibrosis Market CR5 and HHI
  11. 4.6.3 2025 Kidney (Renal) Fibrosis Tier 1, Tier 2, and Tier 3
5 Kidney (Renal) Fibrosis Market Size by Type
  1. 5.1 Global Kidney (Renal) Fibrosis Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Kidney (Renal) Fibrosis Revenue by Type (2021-2032)
  3. 5.3 Global Kidney (Renal) Fibrosis Revenue Market Share by Type (2021-2032)
6 Kidney (Renal) Fibrosis Market Size by Application
  1. 6.1 Global Kidney (Renal) Fibrosis Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Kidney (Renal) Fibrosis Revenue by Application (2021-2032)
  3. 6.3 Global Kidney (Renal) Fibrosis Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Merck
  2. 7.1.1 Merck Company Information
  3. 7.1.2 Merck Business Overview
  4. 7.1.3 Merck Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Merck Kidney (Renal) Fibrosis Product Portfolio
  6. 7.1.5 Merck Recent Developments
  7. 7.2 Roche
  8. 7.2.1 Roche Company Information
  9. 7.2.2 Roche Business Overview
  10. 7.2.3 Roche Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Roche Kidney (Renal) Fibrosis Product Portfolio
  12. 7.2.5 Roche Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Kidney (Renal) Fibrosis Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 ProMetic Life-Sciences Inc.
  20. 7.4.1 ProMetic Life-Sciences Inc. Company Information
  21. 7.4.2 ProMetic Life-Sciences Inc. Business Overview
  22. 7.4.3 ProMetic Life-Sciences Inc. Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  23. 7.4.4 ProMetic Life-Sciences Inc. Kidney (Renal) Fibrosis Product Portfolio
  24. 7.4.5 ProMetic Life-Sciences Inc. Recent Developments
  25. 7.5 La Jolla Pharmaceutical Company
  26. 7.5.1 La Jolla Pharmaceutical Company Company Information
  27. 7.5.2 La Jolla Pharmaceutical Company Business Overview
  28. 7.5.3 La Jolla Pharmaceutical Company Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  29. 7.5.4 La Jolla Pharmaceutical Company Kidney (Renal) Fibrosis Product Portfolio
  30. 7.5.5 La Jolla Pharmaceutical Company Recent Developments
  31. 7.6 InterMune
  32. 7.6.1 InterMune Company Information
  33. 7.6.2 InterMune Business Overview
  34. 7.6.3 InterMune Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  35. 7.6.4 InterMune Kidney (Renal) Fibrosis Product Portfolio
  36. 7.6.5 InterMune Recent Developments
  37. 7.7 Genzyme Corporation
  38. 7.7.1 Genzyme Corporation Company Information
  39. 7.7.2 Genzyme Corporation Business Overview
  40. 7.7.3 Genzyme Corporation Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Genzyme Corporation Kidney (Renal) Fibrosis Product Portfolio
  42. 7.7.5 Genzyme Corporation Recent Developments
  43. 7.8 Galectin Therapeutics
  44. 7.8.1 Galectin Therapeutics Company Information
  45. 7.8.2 Galectin Therapeutics Business Overview
  46. 7.8.3 Galectin Therapeutics Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Galectin Therapeutics Kidney (Renal) Fibrosis Product Portfolio
  48. 7.8.5 Galectin Therapeutics Recent Developments
  49. 7.9 BioLine Rx Ltd
  50. 7.9.1 BioLine Rx Ltd Company Information
  51. 7.9.2 BioLine Rx Ltd Business Overview
  52. 7.9.3 BioLine Rx Ltd Kidney (Renal) Fibrosis Revenue and Gross Margin (2021-2026)
  53. 7.9.4 BioLine Rx Ltd Kidney (Renal) Fibrosis Product Portfolio
  54. 7.9.5 BioLine Rx Ltd Recent Developments
8 North America
  1. 8.1 North America Kidney (Renal) Fibrosis Revenue (2021-2032)
  2. 8.2 North America Kidney (Renal) Fibrosis Revenue by Type (2021-2032)
  3. 8.2.1 North America Kidney (Renal) Fibrosis Revenue by Type (2021-2026)
  4. 8.2.2 North America Kidney (Renal) Fibrosis Revenue by Type (2027-2032)
  5. 8.3 North America Kidney (Renal) Fibrosis Revenue Share by Type (2021-2032)
  6. 8.4 North America Kidney (Renal) Fibrosis Revenue by Application (2021-2032)
  7. 8.4.1 North America Kidney (Renal) Fibrosis Revenue by Application (2021-2026)
  8. 8.4.2 North America Kidney (Renal) Fibrosis Revenue by Application (2027-2032)
  9. 8.5 North America Kidney (Renal) Fibrosis Revenue Share by Application (2021-2032)
  10. 8.6 North America Kidney (Renal) Fibrosis Revenue by Country
  11. 8.6.1 North America Kidney (Renal) Fibrosis Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Kidney (Renal) Fibrosis Revenue by Country (2021-2026)
  13. 8.6.3 North America Kidney (Renal) Fibrosis Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Kidney (Renal) Fibrosis Revenue (2021-2032)
  2. 9.2 Europe Kidney (Renal) Fibrosis Revenue by Type (2021-2032)
  3. 9.2.1 Europe Kidney (Renal) Fibrosis Revenue by Type (2021-2026)
  4. 9.2.2 Europe Kidney (Renal) Fibrosis Revenue by Type (2027-2032)
  5. 9.3 Europe Kidney (Renal) Fibrosis Revenue Share by Type (2021-2032)
  6. 9.4 Europe Kidney (Renal) Fibrosis Revenue by Application (2021-2032)
  7. 9.4.1 Europe Kidney (Renal) Fibrosis Revenue by Application (2021-2026)
  8. 9.4.2 Europe Kidney (Renal) Fibrosis Revenue by Application (2027-2032)
  9. 9.5 Europe Kidney (Renal) Fibrosis Revenue Share by Application (2021-2032)
  10. 9.6 Europe Kidney (Renal) Fibrosis Revenue by Country
  11. 9.6.1 Europe Kidney (Renal) Fibrosis Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Kidney (Renal) Fibrosis Revenue by Country (2021-2026)
  13. 9.6.3 Europe Kidney (Renal) Fibrosis Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Kidney (Renal) Fibrosis Revenue (2021-2032)
  2. 10.2 China Kidney (Renal) Fibrosis Revenue by Type (2021-2032)
  3. 10.2.1 China Kidney (Renal) Fibrosis Revenue by Type (2021-2026)
  4. 10.2.2 China Kidney (Renal) Fibrosis Revenue by Type (2027-2032)
  5. 10.3 China Kidney (Renal) Fibrosis Revenue Share by Type (2021-2032)
  6. 10.4 China Kidney (Renal) Fibrosis Revenue by Application (2021-2032)
  7. 10.4.1 China Kidney (Renal) Fibrosis Revenue by Application (2021-2026)
  8. 10.4.2 China Kidney (Renal) Fibrosis Revenue by Application (2027-2032)
  9. 10.5 China Kidney (Renal) Fibrosis Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Kidney (Renal) Fibrosis Revenue (2021-2032)
  2. 11.2 Asia Kidney (Renal) Fibrosis Revenue by Type (2021-2032)
  3. 11.2.1 Asia Kidney (Renal) Fibrosis Revenue by Type (2021-2026)
  4. 11.2.2 Asia Kidney (Renal) Fibrosis Revenue by Type (2027-2032)
  5. 11.3 Asia Kidney (Renal) Fibrosis Revenue Share by Type (2021-2032)
  6. 11.4 Asia Kidney (Renal) Fibrosis Revenue by Application (2021-2032)
  7. 11.4.1 Asia Kidney (Renal) Fibrosis Revenue by Application (2021-2026)
  8. 11.4.2 Asia Kidney (Renal) Fibrosis Revenue by Application (2027-2032)
  9. 11.5 Asia Kidney (Renal) Fibrosis Revenue Share by Application (2021-2032)
  10. 11.6 Asia Kidney (Renal) Fibrosis Revenue by Country
  11. 11.6.1 Asia Kidney (Renal) Fibrosis Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Kidney (Renal) Fibrosis Revenue by Country (2021-2026)
  13. 11.6.3 Asia Kidney (Renal) Fibrosis Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Kidney (Renal) Fibrosis Revenue (2021-2032)
  2. 12.2 SAMEA Kidney (Renal) Fibrosis Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Kidney (Renal) Fibrosis Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Kidney (Renal) Fibrosis Revenue by Type (2027-2032)
  5. 12.3 SAMEA Kidney (Renal) Fibrosis Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Kidney (Renal) Fibrosis Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Kidney (Renal) Fibrosis Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Kidney (Renal) Fibrosis Revenue by Application (2027-2032)
  9. 12.5 SAMEA Kidney (Renal) Fibrosis Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Kidney (Renal) Fibrosis Revenue by Country
  11. 12.6.1 SAMEA Kidney (Renal) Fibrosis Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Kidney (Renal) Fibrosis Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Kidney (Renal) Fibrosis Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst